Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) announced interim six-month results from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE